Table 3.

Study design and endpoints.

Author [reference]	Study design	N	Patients included	Troponin assay	HFABP assay	Time of HFABP sample	Follow up	Study end points relevant to review
Reiter [9]	Prospective observational study	1074	Suspected ACS	Roche. HS cTnT.	QuickSenshFABP assay	NR	12 months	All-cause mortality
Viswanathan [12]	Prospective observational study	955	Suspected ACS	Siemens Healthcare Diagnostics. Advia TnI /Advia TnI Ultra.	Randox Laboratories	< 12 hours post symptom onset	12 months min; median 18 months	Composite of death and readmission with MI
McCann [11]	Prospective observational study	550	Suspected ACS	Roche, Elecsys, Troponin T mmunoassay	Human H-FABP ELISA test kit, Hycult, biotechnology	Median time 6 hours post symptom onset	12 months	Composite of death and MI
Ilva [14]	Post hoc analysis	293	Suspected ACS	Abbott Diagnostic Division. Architect STAT Troponin I assay.	Innotrac Diagnostics (experimental assaty)	0-24 hours post symptom onset	6 months	Death and readmission with MI
Kilcullen [7]	Post hoc analysis	1448	Confirmed ACS EMMANCE-2 study	Beckman Coulter. Accu TnI assay.	Dainippon Pharmaceutical	12-24 hours post symptom onset	12 months	Death
O’Donoghue [13]	Post hoc analysis	2287	Confirmed ACS OPUS-TIMI 16.	Biosite Diagnostics. Troponin I assay.	Dainippon Pharmaceutical	41±20 hours post randomisation.	10 months	Death, MI
Ishii [10]	Prospective observational study	328	Confirmed ACS	Roche Diagnostics. Elecsys Troponin T immunoassay.	Dainippon Pharmaceutical	NR	6months	Cardiac death and MI

NR = not reported. Revasc = coronary revascularisation, CP= chest pain, CHF= chronic heart failure, MI= myocardial infarction.